CELULARITY INC-A (CELU) Stock Price, Forecast & Analysis
USA - NASDAQ:CELU - US1511902041 - Common Stock
CELU Key Statistics, Chart & Performance
The current stock price of CELU is 1.77 USD. In the past month the price decreased by -13.24%. In the past year, price decreased by -28.05%.
CELU Latest News, Press Relases and Analysis
CELU Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.14 | 386.36B | ||
| AMGN | AMGEN INC | 14.8 | 174.25B | ||
| GILD | GILEAD SCIENCES INC | 14.43 | 146.60B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.26 | 107.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 69.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 866.08 | 57.90B | ||
| INSM | INSMED INC | N/A | 40.57B | ||
| NTRA | NATERA INC | N/A | 28.36B | ||
| BIIB | BIOGEN INC | 9.33 | 22.91B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.89 | 14.88B |
Related stock screener links
About CELU
Company Profile
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 123 full-time employees. The company went IPO on 2019-05-23. The firm is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. The company develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Company Info
CELULARITY INC-A
170 Park Ave
Florham Park NEW JERSEY US
Employees: 120
Phone: 19087682170
CELULARITY INC-A / CELU FAQ
What does CELULARITY INC-A do?
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 123 full-time employees. The company went IPO on 2019-05-23. The firm is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. The company develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Can you provide the latest stock price for CELULARITY INC-A?
The current stock price of CELU is 1.77 USD. The price decreased by -0.56% in the last trading session.
Does CELULARITY INC-A pay dividends?
CELU does not pay a dividend.
What is the ChartMill rating of CELULARITY INC-A stock?
CELU has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting CELU stock to perform?
7 analysts have analysed CELU and the average price target is 6.12 USD. This implies a price increase of 245.76% is expected in the next year compared to the current price of 1.77.
Can you provide the sector and industry classification for CELULARITY INC-A?
CELULARITY INC-A (CELU) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for CELULARITY INC-A?
The Revenue of CELULARITY INC-A (CELU) is expected to grow by 27.37% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CELU Technical Analysis
CELU Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CELU. CELU has a bad profitability rating. Also its financial health evaluation is rather negative.
CELU Financial Highlights
Over the last trailing twelve months CELU reported a non-GAAP Earnings per Share(EPS) of -3.19. The EPS increased by 44.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.3% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CELU Forecast & Estimates
7 analysts have analysed CELU and the average price target is 6.12 USD. This implies a price increase of 245.76% is expected in the next year compared to the current price of 1.77.
For the next year, analysts expect an EPS growth of -752.63% and a revenue growth 27.37% for CELU